Overview

Radio-immunotherapy (CDX-301, Radiotherapy, CDX-1140 and Poly-ICLC) for the Treatment of Unresectable or Metastatic Breast Cancer Patients

Status:
Not yet recruiting

Trial end date:
2023-11-15

Target enrollment:

Participant gender:

Summary

This phase I trial evaluates the side effects of radio-immunotherapy (CDX-301, radiotherapy, CDX-1140 and Poly-ICLC) in treating patients with breast cancer that cannot be removed by surgery (unresectable) and has spread to other places in the body (metastatic). CDX-301 may induce cross-presenting dendritic cells, master regulators in the immune system. Radiation therapy uses high energy to kill tumor cells and release antigens that may be picked up, processed and presented by cross-presenting dendritic cells. CDX-1140 and Poly-ICLC may activate tumor antigen-loaded,cross-presenting dendritic cells, and generate tumor-specific T lymphocytes, a type of immune cells, that can search out and attack cancers. Giving immune modulators and radiation therapy may stimulate tumor cell death and activate the immune system.

Phase:

Phase 1

Details

Lead Sponsor:

Roswell Park Cancer Institute

Treatments:

Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Carboxymethylcellulose Sodium
Flt3 ligand protein
Immunoglobulins
Poly I-C
Poly ICLC